NCT07487883Recruiting
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
A Single-arm, Open-label, Single-center Clinical Study to Evaluate CDH3-targeted Positron Emission Tomography (PET) for Lung Malignant Tumors
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- 18 Mar 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07487883
What you commit to
- Study type: Observational
- Planned participants: 80
- From 18 Mar 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of other malignant tumors or prior receipt of other anti-tumor therapies;
- Presence of claustrophobia or other mental illnesses;
- Any other conditions deemed by the investigators as inappropriate for participation in this study.
Other
- Women who are planning pregnancy, pregnant, or breastfeeding;
- Poor or missing PET scan image quality of the probe that fails to meet analysis standards;
Who the study is looking for
- Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;
- Availability of complete clinical and imaging data;
- Life expectancy ≥ 12 weeks;
- Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹/L or neutrophils ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;
- Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria;
- Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks;
- Ability to provide adequate tumor tissue for testing and research.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.